Ocular Updates Plans for Axpaxli NDA for Wet AMD

Viridian Executive Discusses FDA Approval of New TED Therapy

An executive from Viridian discusses the FDA approval of Lumvoa for thyroid eye disease (TED); a biosimilar referencing Lucentis is relaunched in the US; and Lumibird introduces a wireless integrated laser-indirect-ophthalmoscope. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Ocular Updates Plans for Axpaxli NDA for Wet AMD

Ocular Therapeutix provides a key update on its NDA plans for wet AMD drug candidate Axpaxli; Thea US launches a first-of-its-kind eye gel for glaucoma; and there were several recent milestones reached in the clinical development of novel drugs for a variety of ocular conditions. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Tecnis PureSee IOL Fully Launched in the US

Johnson & Johnson expands the availability of its latest Tecnis lens; Bayer completes its acquisition of Perfuse Therapeutics, expanding its presence in ophthalmology; and ophthalmic leaders discuss how to navigate the current regulatory environment of the FDA. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Study Examines Semaglutide and Wet AMD Risk

An international study examines the link between a popular weight loss medication and wet AMD risk; Heidelberg receives FDA clearance for a Spectralis software upgrade; and Bausch + Lomb launches its latest over-the-counter dry eye relief product in the US. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Oculis Announces Phase 3 Results for DME Eye Drops

Oculis Releases phase 3 data for its investigational eye drop for DME; Rayner expands its surgical offerings with the launch of a new OVD; and a biosimilar referencing Eylea is launched in Europe. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]